Fredda sells ALXN 160.43: FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
CHESHIRE, Conn., Jun 17, 2014 (BUSINESS WIRE) -- Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with . ... ...
16 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home